Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer

International Journal of Cancer

Volumn 136, Issue 1, 2015, Pages 83-90

  Schirripa, Marta ^a   Cremolini, Chiara ^a   Loupakis, Fotios ^a   Morvillo, Manfredi ^a   Bergamo, Francesca ^b   Zoratto, Federica ^a   Salvatore, Lisa ^a   Antoniotti, Carlotta ^a   Marmorino, Federica ^a   Sensi, Elisa ^a   Lupi, Cristiana ^a   Fontanini, Gabriella ^a   Gregorio, Veronica De ^a   Giannini, Riccardo ^a   Basolo, Fulvio ^a   Masi, Gianluca ^a   Falcone, Alfredo ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

anti EGFR; BRAF; KRAS; metastatic colorectal cancer; NRAS

Indexed keywords

B RAF KINASE; CETUXIMAB; IRINOTECAN; PANITUMUMAB; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL FEATURE; CODON; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG RESPONSE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HISTOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUTATION RATE; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PERITONEUM METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; TUMOR LOCALIZATION; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETIC ASSOCIATION; GENETICS; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MISSENSE MUTATION; MORTALITY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC ASSOCIATION STUDIES; GTP PHOSPHOHYDROLASES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION, MISSENSE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84925282897     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28955     Document Type: Article

References (53)

1. Malumbres M, Barbacid M,. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3: 459-65.
2. Bos JL,. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-9.
3. Kirsten WH, Schauf V, McCoy J. Properties of a murine sarcoma virus. Bibl Haematol 1970: 246-9.
4. Harvey JJ,. An unidentified virus which causes the rapid production of tumours in mice. Nature 1964; 204: 1104-5.
5. Cooper GM,. Cellular transforming genes. Science 1982; 217: 801-6.
6. Shimizu K, Goldfarb M, Perucho M, et al., Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line. Proc Natl Acad Sci USA 1983; 80: 383-7.
7. Conlin A, Smith G, Carey FA, et al., The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 2005; 54: 1283-6.
8. Downward J,. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
9. http://cancer.sanger.ac.uk/cosmic/gene/overview?ln=KRAS.
10. Fernandez-Medarde A, Santos E,. Ras in cancer and developmental diseases. Genes Cancer 2011; 2: 344-58.
11. Smith CG, Fisher D, Claes B, et al., Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy +/- cetuximab. Clin Cancer Res 2013; 19: 4104-13.
12. Van Cutsem E, Kohne CH, Lang I, et al., Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-19.
13. Bokemeyer C, Bondarenko I, Hartmann JT, et al., Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22: 1535-46.
14. Lievre A, Bachet JB, Le Corre D, et al., KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-5.
15. Amado RG, Wolf M, Peeters M, et al., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
16. Vale CL, Tierney JF, Fisher D, et al., Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev 2012; 38: 618-25.
17. Loupakis F, Cremolini C, Salvatore L, et al., Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. Cancer 2012; 118: 1523-32.
18. Loupakis F, Ruzzo A, Cremolini C, et al., KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-21.
19. Tran B, Kopetz S, Tie J, et al., Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117: 4623-32.
20. Cejas P, Lopez-Gomez M, Aguayo C, et al., KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 2009; 4: e8199.
21. Tie J, Lipton L, Desai J, et al., KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res 2011; 17: 1122-30.
22. Roth AD, Tejpar S, Delorenzi M, et al., Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-74.
23. Ogino S, Meyerhardt JA, Irahara N, et al., KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009; 15: 7322-9.
24. Richman SD, Seymour MT, Chambers P, et al., KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27: 5931-7.
25. Andreyev HJ, Norman AR, Cunningham D, et al., Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85: 692-6.
26. Hutchins G, Southward K, Handley K, et al., Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011; 29: 1261-70.
27. Moelling K, Heimann B, Beimling P, et al., Serine- and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins. Nature 1984; 312: 558-61.
28. Kyriakis JM, App H, Zhang XF, et al., Raf-1 activates MAP kinase-kinase. Nature 1992; 358: 417-21.
29. Davies H, Bignell GR, Cox C, et al., Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
30. Saridaki Z, Papadatos-Pastos D, Tzardi M, et al., BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. Br J Cancer 2010; 102: 1762-8.
31. Souglakos J, Philips J, Wang R, et al., Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009; 101: 465-72.
32. Yokota T, Ura T, Shibata N, et al., BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 2011; 104: 856-62.
33. Popovici V, Budinska E, Tejpar S, et al., Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol 2012; 30: 1288-95.
34. Tie J, Gibbs P, Lipton L, et al., Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 2011; 128: 2075-84.
35. Samowitz WS, Albertsen H, Sweeney C, et al., Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 2006; 98: 1731-8.
36. De Roock W, Claes B, Bernasconi D, et al., Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62.
37. Di Nicolantonio F, Martini M, Molinari F, et al., Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-12.
38. Seymour MT, Brown SR, Middleton G, et al., Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013; 14: 749-59.
39. Kopetz S, Desai J, Chan E, et al., PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 2010; 28:269s, (suppl; abstr 3534)
40. Maughan TS, Adams RA, Smith CG, et al., Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-14.
41. Fornaro L, Lonardi S, Masi G, et al., FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 2013; 24: 2062-7.
42. Douillard JY, Oliner KS, Siena S, et al., Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-34.
43. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000741/WC500047710.pdf.
44. Andre T, Blons H, Mabro M, et al., Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol 2013; 24: 412-19.
45. Peeters M, Oliner KS, Parker A, et al., Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 2013; 19: 1902-12.
46. Vaughn CP, Zobell SD, Furtado LV, et al., Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011; 50: 307-12.
47. Stintzing S, Jung A, Rossius L, et al., LATE BREAKING ABSTRACT: analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Presented at European Cancer Congress 2013, September 27 to October 1, 2013, Amsterdam, The Netherlands Abstract LBA17, 2013.
48. Tejpar S, Lenz HJ, Köhne C, et al., Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: new results from the OPUS study. J Clin Oncol 2014; 32 (suppl 3; abstr LBA444).
49. Peeters M, Oliner KS, Price TJ, et al., Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 2014; 32 (suppl 3; abstr LBA387).
50. Schwartzberg LS, Rivera F, Karthaus M, et al., PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS Exon 2 metastatic colorectal cancer. J Clin Oncol, 2014 Apr 21. [Epub ahead of print].
51. Goldstein J, Tran B, Ensor J, et al., Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 2014; 25: 1032-8.
52. Haigis KM, Kendall KR, Wang Y, et al., Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008; 40: 600-8.
53. Wang Y, Velho S, Vakiani E, et al., Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression. Cancer Discov 2013; 3: 294-307.